Skip to Main Content

Paper Details

Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.
Cell Rep Med
24
2021
CPT1A, FAO, HGSOC, HGSOC cells, RNA, carboplatin, fatty acid, high-grade serous ovarian cancer, intra-patient cell line pairs, patient, patients, platinum, ptrc-cell, resistant cells, sensitive, xenograft models
Author NameAffiliation
Shrabanti ChowdhuryIcahn School of Medicine at Mount Sinai
Sara R SavageBaylor College of Medicine
Jacob J KennedyClinical Research Division, Fred Hutchinson Cancer Research Center
Jeffrey R WhiteakerClinical Research Division, Fred Hutchinson Cancer Research Center
Chenwei LinClinical Research Division, Fred Hutchinson Cancer Research Center
Chenwei LinClinical Research Division, Fred Hutchinson Cancer Research Center
Ann L ObergMayo Clinic
Melissa C LarsonDivision of Clinical Trials and Biostatistics, Mayo Clinic
Steven P GygiHarvard Medical School
Steven P GygiHarvard Medical School
Andrew N HoofnagleUniversity of Washington
Saravut J WerohaMayo Clinic
Scott H KaufmannMayo Clinic
Scott H KaufmannMayo Clinic
Pei WangIcahn School of Medicine at Mount Sinai
Michael J BirrerUniversity of Arkansas for Medical Sciences
Amanda G PaulovichClinical Research Division, Fred Hutchinson Cancer Research Center
  • 1 - 17

Datasets

Release 1.2